O	0	1	A
O	2	12	Randomized
O	13	23	Controlled
O	24	29	Trial
O	30	32	of
O	33	36	the
O	37	44	Effects
O	45	47	of
B-intervention	48	59	Mindfulness
I-intervention	59	60	-
I-intervention	60	65	Based
I-intervention	66	72	Stress
I-intervention	73	82	Reduction
I-intervention	83	84	(
I-intervention	84	88	MBSR
I-intervention	88	89	[
I-intervention	89	91	BC
I-intervention	91	92	]
I-intervention	92	93	)
O	94	96	on
O	97	103	Levels
O	104	106	of
O	107	119	Inflammatory
O	120	130	Biomarkers
O	131	136	Among
B-eligibility	137	147	Recovering
I-eligibility	148	154	Breast
I-eligibility	155	161	Cancer
I-eligibility	162	171	Survivors
O	171	172	.

O	173	176	The
O	177	184	purpose
O	185	187	of
O	188	192	this
O	193	201	substudy
O	202	204	of
O	205	206	a
O	207	212	large
O	213	223	randomized
O	224	234	controlled
O	235	240	trial
O	241	244	was
O	245	247	to
O	248	256	evaluate
O	257	260	the
O	261	269	efficacy
O	270	272	of
O	273	276	the
O	277	288	Mindfulness
O	288	289	-
O	289	294	Based
O	295	301	Stress
O	302	311	Reduction
O	312	313	(
O	313	319	Breast
O	320	326	Cancer
O	326	327	)
O	328	329	(
O	329	333	MBSR
O	333	334	[
O	334	336	BC
O	336	337	]
O	337	338	)
O	339	346	program
O	347	355	compared
O	356	358	to
B-control	359	364	usual
I-control	365	369	care
I-control	370	371	(
I-control	371	373	UC
I-control	373	374	)
O	375	377	in
O	378	389	normalizing
O	390	395	blood
O	396	402	levels
O	403	405	of
O	406	409	pro
O	409	410	-
O	410	422	inflammatory
O	423	432	cytokines
O	433	438	among
O	439	445	breast
O	446	452	cancer
O	453	462	survivors
O	463	464	(
O	464	467	BCS
O	467	468	)
O	468	469	.

O	470	471	A
O	472	477	total
O	478	480	of
B-total-participants	481	484	322
O	485	488	BCS
O	489	493	were
O	494	504	randomized
O	505	507	to
O	508	514	either
O	515	516	a
O	517	518	6
O	518	519	-
O	519	523	week
O	524	528	MBSR
O	528	529	(
O	529	531	BC
O	531	532	)
O	533	540	program
O	541	543	or
O	544	545	a
O	546	548	UC
O	548	549	.

O	550	552	At
O	553	561	baseline
O	562	565	and
O	566	567	6
O	568	571	and
O	572	574	12
O	575	580	weeks
O	580	581	,
O	582	584	10
O	585	587	ml
O	588	590	of
O	591	597	venous
O	598	603	blood
O	604	607	and
O	608	619	demographic
O	620	623	and
O	624	632	clinical
O	633	637	data
O	638	642	were
O	643	652	collected
O	653	656	and
O	656	657	/
O	657	659	or
O	660	667	updated
O	667	668	.

O	669	675	Plasma
O	676	685	cytokines
O	686	687	(
O	687	698	interleukin
O	699	700	[
O	700	702	IL
O	702	703	]
O	703	704	-
O	704	705	1
O	705	706	β
O	706	707	,
O	708	710	IL
O	710	711	-
O	711	712	6
O	712	713	,
O	714	716	IL
O	716	717	-
O	717	719	10
O	719	720	,
O	721	726	tumor
O	727	735	necrosis
O	736	742	factor
O	743	744	[
O	744	747	TNF
O	747	748	]
O	749	750	α
O	750	751	,
O	752	764	transforming
O	765	771	growth
O	772	778	factor
O	779	780	[
O	780	783	TGF
O	783	784	]
O	785	786	β
O	786	787	1
O	787	788	,
O	789	796	soluble
O	797	802	tumor
O	803	811	necrosis
O	812	818	factor
O	819	827	receptor
O	828	829	[
O	829	834	sTNFR
O	834	835	]
O	836	837	1
O	837	838	)
O	839	843	were
O	844	851	assayed
O	851	852	.

O	853	859	Linear
O	860	865	mixed
O	866	872	models
O	873	877	were
O	878	882	used
O	883	885	to
O	886	892	assess
O	893	901	cytokine
O	902	908	levels
O	909	915	across
O	916	921	three
O	922	926	time
O	927	933	points
O	934	935	(
O	935	943	baseline
O	944	947	and
O	948	949	6
O	950	953	and
O	954	956	12
O	957	962	weeks
O	962	963	)
O	964	966	by
O	967	972	group
O	973	974	(
O	974	978	MBSR
O	978	979	[
O	979	981	BC
O	981	982	]
O	983	985	vs
O	985	986	.
O	987	989	UC
O	989	990	)
O	990	991	.

O	992	994	Of
O	995	998	the
O	999	1002	six
O	1003	1011	measured
O	1012	1021	cytokines
O	1021	1022	,
O	1023	1028	three
O	1029	1033	were
B-outcome	1034	1047	nondetectable
O	1048	1050	at
O	1051	1056	rates
O	1057	1064	greater
O	1065	1069	than
O	1070	1072	50
O	1072	1073	%
O	1074	1075	(
O	1075	1077	IL
O	1077	1078	-
O	1078	1080	10
O	1080	1081	,
O	1082	1084	IL
O	1084	1085	-
O	1085	1086	1
O	1086	1087	β
O	1087	1088	,
O	1089	1092	TGF
O	1092	1093	-
O	1093	1094	β
O	1094	1095	1
O	1095	1096	)
O	1097	1100	and
O	1100	1101	,
O	1102	1109	because
O	1110	1112	of
O	1113	1120	overall
O	1121	1124	low
O	1125	1135	prevalence
O	1135	1136	,
O	1137	1141	were
O	1142	1145	not
O	1146	1154	analyzed
O	1155	1162	further
O	1162	1163	.

O	1164	1167	For
O	1168	1171	the
O	1172	1181	remaining
O	1182	1191	cytokines
O	1192	1193	(
O	1193	1196	TNF
O	1196	1197	α
O	1197	1198	,
O	1199	1201	IL
O	1201	1202	-
O	1202	1203	6
O	1203	1204	,
O	1205	1211	sTNFR1
O	1211	1212	)
O	1212	1213	,
O	1214	1221	results
O	1222	1228	showed
O	1229	1233	that
B-outcome	1234	1237	TNF
I-outcome	1237	1238	α
I-outcome	1239	1242	and
I-outcome	1243	1245	IL
I-outcome	1245	1246	-
I-outcome	1246	1247	6
O	1248	1257	increased
O	1258	1264	during
O	1265	1268	the
O	1269	1275	follow
O	1275	1276	-
O	1276	1278	up
O	1279	1285	period
O	1286	1287	(
O	1287	1294	between
O	1295	1296	6
O	1297	1300	and
O	1301	1303	12
O	1304	1309	weeks
O	1309	1310	)
O	1311	1317	rather
O	1318	1322	than
O	1323	1329	during
O	1330	1333	the
O	1334	1338	MBSR
O	1338	1339	(
O	1339	1341	BC
O	1341	1342	)
O	1343	1351	training
O	1352	1358	period
O	1359	1360	(
O	1360	1367	between
O	1368	1376	baseline
O	1377	1380	and
O	1381	1382	6
O	1383	1388	weeks
O	1388	1389	)
O	1389	1390	,
O	1391	1396	while
B-outcome	1397	1403	sTNFR1
I-outcome	1404	1410	levels
O	1411	1414	did
O	1415	1418	not
O	1419	1425	change
O	1426	1439	significantly
O	1440	1446	across
O	1447	1450	the
O	1451	1453	12
O	1453	1454	-
O	1454	1458	week
O	1459	1465	period
O	1465	1466	.

O	1467	1472	Study
O	1473	1480	results
O	1481	1488	suggest
O	1489	1493	that
O	1494	1498	MBSR
O	1498	1499	(
O	1499	1501	BC
O	1501	1502	)
O	1503	1510	affects
O	1511	1519	cytokine
O	1520	1526	levels
O	1527	1529	in
O	1530	1533	BCS
O	1533	1534	,
O	1535	1541	mainly
O	1542	1546	with
O	1547	1556	increases
O	1557	1559	in
O	1560	1563	TNF
O	1563	1564	α
O	1565	1568	and
O	1569	1571	IL
O	1571	1572	-
O	1572	1573	6
O	1573	1574	.

O	1575	1578	The
O	1579	1583	data
O	1584	1591	further
O	1592	1599	suggest
O	1600	1604	that
O	1605	1606	B
O	1606	1607	-
O	1607	1611	cell
O	1612	1622	modulation
O	1623	1626	may
O	1627	1629	be
O	1630	1631	a
O	1632	1636	part
O	1637	1639	of
O	1640	1646	immune
O	1647	1655	recovery
O	1656	1662	during
O	1663	1669	breast
O	1670	1676	cancer
O	1677	1687	management
O	1688	1691	and
O	1692	1696	that
O	1697	1706	increases
O	1707	1709	in
O	1710	1713	TNF
O	1713	1714	α
O	1715	1718	and
O	1719	1721	IL
O	1721	1722	-
O	1722	1723	6
O	1724	1727	may
O	1728	1730	be
O	1731	1738	markers
O	1739	1742	for
O	1743	1747	MBSR
O	1747	1748	(
O	1748	1750	BC
O	1750	1751	)
O	1751	1752	-
O	1752	1759	related
O	1760	1768	recovery
O	1768	1769	.
